Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $58.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price hoisted by Jefferies Financial Group from $54.00 to $58.00 in a report issued on Thursday,Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on TARS. HC Wainwright restated a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Barclays decreased their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Finally, Guggenheim reissued a “buy” rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $63.67.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $43.57 on Thursday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.67 billion, a P/E ratio of -11.44 and a beta of 1.05. The firm has a fifty day moving average of $50.14 and a 200-day moving average of $43.61. Tarsus Pharmaceuticals has a 52-week low of $20.08 and a 52-week high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. As a group, analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Institutional Trading of Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of TARS. Summit Investment Advisors Inc. grew its position in shares of Tarsus Pharmaceuticals by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock worth $213,000 after acquiring an additional 244 shares in the last quarter. Sherbrooke Park Advisers LLC boosted its holdings in Tarsus Pharmaceuticals by 7.2% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company’s stock worth $364,000 after purchasing an additional 443 shares during the period. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $25,000. Bank of New York Mellon Corp lifted its position in shares of Tarsus Pharmaceuticals by 0.5% in the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company’s stock worth $5,644,000 after buying an additional 498 shares during the last quarter. Finally, Swiss National Bank lifted its position in shares of Tarsus Pharmaceuticals by 1.2% in the 4th quarter. Swiss National Bank now owns 52,333 shares of the company’s stock worth $2,898,000 after buying an additional 600 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.